Table 2.
Patient characteristics according to progression, complete response, and relapse.
| Progression n (%) | Complete Response n (%) | Relapse n (%) | |||||
|---|---|---|---|---|---|---|---|
| No | Yes | No | Yes | No | Yes | ||
| Gender | Female | 74 (56.5) | 20 (37.0) | 36 (50.7) | 58 (50.9) | 25 (55.6) | 33 (47.8) |
| Male | 57 (43.5) | 34 (63.0) | 35 (49.3) | 56 (49.1) | 20 (44.4) | 36 (52.2) | |
| Stage at Diagnosis | IA | 54 (41.2) | 22 (40.7) | 22 (31) | 54 (47.4) | 24 (53.3) | 30 (43.5) |
| IB | 53 (40.4) | 20 (37.0) | 28 (39.4) | 45 (39.5) | 16 (35.6) | 29 (42.0) | |
| IIA | 24 (18.3) | 12 (22.3) | 21 (29.6) | 15 (13.1) | 5 (11.1) | 10 (14.5) | |
| T Stage at Diagnosis | T1 | 59 (45.0) | 29 (53.7) | 31 (43.7) | 57 (50.0) | 26 (57.8) | 31 (44.9) |
| T2 | 72 (55.0) | 25 (46.3) | 40 (56.3) | 57 (50.0) | 19 (42.2) | 38 (55.1) | |
| N Stage at Diagnosis | N0 | 67 (51.1) | 15 (27.8) | 24 (33.8) | 58 (50.9) | 24 (53.3) | 34 (49.3) |
| Nx | 40 (30.5) | 27 (50.0) | 26 (36.6) | 41 (36.0) | 16 (35.6) | 25 (36.2) | |
| N1 | 24 (18.4) | 12 (22.2) | 21 (29.6) | 15 (13.1) | 5 (11.1) | 10 (14.5) | |
| B Stage at Diagnosis | B0 | 128 (97.7) | 52 (96.3) | 68 (95.8) | 112 (98.3) | 45 (100) | 67 (95.9) |
| B1 | 3 (2.3) | 2 (3.7) | 3 (4.2) | 2 (1.7) | 0 (0) | 2 (4.1) | |
| Patch/Plaque | Patch | 59 (45.0) | 20 (37.0) | 26 (36.6) | 53 (46.5) | 23 (51.1) | 30 (43.5) |
| Patch + Plaque | 72 (55.0) | 34 (63.0) | 45 (63.4) | 61 (53.5) | 22 (48.9) | 39 (56.5) | |
| Morphological Findings | Erythematous | 88 (67.1) | 32 (59.2) | 48 (67.6) | 72 (63.2) | 27 (60.0) | 45 (63) |
| Hyperpigmented | 27 (20.6) | 8 (14.8) | 13 (18.3) | 22 (19.3) | 8 (17.8) | 14 (16.4) | |
| Poikiloderma | 6 (4.5) | 7 (13.0) | 6 (8.5) | 7 (6.1) | 2 (4.4) | 5 (9.6) | |
| Folliculotropism | 5 (3.8) | 4 (7.4) | 5 (5.6) | 4 (4.4) | 1 (2.2) | 3 (5.5) | |
| PPD-like | 6 (4.5) | 1 (1.9) | 1 (1.4) | 6 (5.3) | 4 (8.9) | 2 (4.1) | |
| Hypopigmented | 2 (1.5) | 1 (1.9) | 0 (0) | 3 (2.6) | 3 (6.7) | 0 | |
| GSS | 0 (0) | 1 (1.9) | 1 (1.4) | 0 (0) | - | - | |
| Ichthyosiform | 0 (0) | 1 (1.9) | 1 (1.4) | 0 (0) | - | - | |
| Pruritus | No | 58 (44.3) | 19 (35.2) | 28 (39.4) | 49 (43.0) | 20 (44.4) | 29 (42.0) |
| Yes | 73 (55.7) | 35 (64.8) | 43 (60.6) | 65 (57.0) | 25 (55.6) | 40 (58.0) | |
| LDH Levels | Normal | 126 (96.2) | 44 (81.5) | 61 (86.0) | 109 (95.6) | 42 (93.3) | 67 (97.1) |
| High | 5 (3.8) | 10 (18.5) | 10 (14.0) | 5 (4.4) | 3 (6.7) | 2 (2.9) | |
| β-2 Microglobulin Levels | Normal | 94 (71.8) | 27 (50.0) | 36 (50.7) | 85 (74.6) | 35 (77.8) | 50 (72.5) |
| High | 37 (28.2) | 27 (50.0) | 35 (49.3) | 29 (25.4) | 10 (22.2) | 19 (27.5) | |
| Eosinophilia | No | 124 (94.7) | 50 (92.6) | 64 (90.1) | 110 (96.5) | 44 (97.8) | 66 (95.7) |
| Yes | 7 (5.3) | 4 (7.4) | 7 (9.9) | 4 (3.5) | 1 (2.2) | 3 (4.3) | |
| Histopathological Findings |
Classic | 90 (68.7) | 29 (53.7) | 39 (55.7) | 80 (85.1) | 30 (66.7) | 50 (72.5) |
| Folliculotropism | 15 (11.5) | 13 (24.0) | 18 (25.7) | 10 (10.6) | 4 (8.9) | 6 (8.7) | |
| LCT | 6 (4.6) | 3 (5.5) | 9 (12.9) | 0 (0) | - | - | |
| PPD-like | 4 (3.1) | 1 (1.9) | 2 (2.9) | 3 (3.2) | 1 (2.2) | 2 (2.9) | |
| GSS | 0 (0) | 1 (1.9) | 1 (1.4) | 0 (0) | - | - | |
| Syringotropic | 1 (0.7) | 0 (0) | 0 (0) | 1 (1.1) | 0 (0) | 1 (1.4) | |
| Granuloma Annulare-like | 1 (0.7) | 0 (0) | 1 (1.4) | 0 (0) | - | - | |
| Immunohistochemical Findings | CD4 (+) CD8 (−) | 113 (86.3) | 40 (74.0) | 61 (81.3) | 92 (80.9) | 33 (73.3) | 59 (85.5) |
| CD4 (−) CD8 (+) | 22 (16.8) | 6 (11.1) | 8 (10.7) | 20 (17.5) | 11 (24.4) | 9 (13.0) | |
| CD4 (−) CD8 (−) | 0 (0) | 2 (3.7) | 1 (1.3) | 1 (0.8) | 0 (0) | 1 (1.4) | |
| CD4 (+) CD8 (+) | 1 (0.7) | 1 (1.9) | 1 (1.3) | 1 (0.8) | 1 (2.2) | 0 (0) | |
| CD30 (+) | 1 (0.7) | 3 (5.5) | 4 (5.4) | 0 (0) | - | - | |
| Initial Treatment Type | Skin-directed | 111 (84.7) | 38 (70.3) | 52 (73.2) | 97 (85.1) | 39 (86.7) | 58 (84.1) |
| Systemic | 1 (0.7) | 5 (9.3) | 4 (5.6) | 2 (1.7) | 0 (0) | 2 (2.9) | |
| Combined | 19 (14.5) | 11 (20.4) | 15 (21.1) | 15 (13.2) | 3 (13.3) | 12 (13.0) | |
| Initial Treatment | Topical Corticosteroid | 4 (3.1) | 2 (3.7) | 3 (4.2) | 3 (2.6) | 0 (0) | 3 (5.5) |
| Bexarotene Gel | 1 (0.7) | 0 (0) | 0 (0) | 1 (0.8) | 1 (2.2) | 0 (0) | |
| nbUVB | 51 (38.9) | 14 (25.9) | 22 (31.0) | 43 (37.7) | 18 (40.0) | 25 (36.2) | |
| PUVA | 55 (41.9) | 21 (38.8) | 27 (38.0) | 49 (43.0) | 18 (40.0) | 31 (44.9) | |
| PUVA + Bexarotene Gel | 0 (0) | 1 (1.9) | 0 (0) | 1 (0.8) | 0 (0) | 1 (1.4) | |
| Methotrexate (MTX) | 1 (0.7) | 1 (1.9) | 1 (1.4) | 1 (0.8) | 1 (2.2) | 0 (0) | |
| Acitretin | 1 (0.7) | 2 (3.7) | 2 (2.8) | 1 (0.8) | 1 (2.2) | 0 (0) | |
| Interferon (IFN) | 0 (0.7) | 1 (1.9) | 1 (1.4) | 0 (0) | - | - | |
| nbUVB + Acitretin | 1 (0.7) | 0 (0) | 0 (0) | 1 (0.8) | 1 (2.2) | 0 (0) | |
| nbUVB + IFN | 0 (0) | 1 (1.9) | 1 (1.4) | 0 (0) | - | - | |
| PUVA + Acitretin | 2 (1.5) | 0 (0) | 1 (1.4) | 1 (0.8) | 0 (0) | 1 (1.4) | |
| PUVA + IFN | 13 (9.9) | 11 (20.4) | 13(18.3) | 11 (9.6) | 3 (6.7) | 8 (11.6) | |
| PUVA + MTX | 1 (0.7) | 0 (0) | 0 (0) | 1 (0.8) | 1 (2.2) | 0 (0) | |
| ECP + IFN | 1 (0.7) | 0 (0) | 0 (0) | 1 (0.8) | 1 (2.2) | 0 (0) | |
| Age at Diagnosis | 50.6 | 51.2 | 52.4 | 49.8 | 53 | 47.7 | |
| Age of Onset of Lesions (Years) | 46.3 | 44.9 | 47.6 | 44.8 | 48.3 | 42.5 | |
| Follow-up Time (Years) | 5.1 | 6.8 | 5.7 | 5.5 | 3.0 | 7.1 | |
| Time from Appearance to Diagnosis (Months) | 52.1 | 66.5 | 57.4 | 55.6 | 42.5 | 64.1 | |
Pigmented Purpuric Dermatosis (PPD); Granulomatous Slack Skin (GSS); lactate dehydrogenase (LDH); Large Cell Transformation (LCT); Narrowband Ultraviolet B (nbUVB); Psoralen Ultraviolet A (PUVA); Methotrexate (MTX); Interferon (IFN); Extracorporeal Photopheresis.